Effects of placebos without deception compared with no treatment: A systematic review and meta‐analysis. Issue 2 (30th May 2017)

• Record Type: Journal Article
• Authors: Charlesworth, James E.G.; Petkovic, Grace; Kelley, John M.; Hunter, Monika; Onakpoya, Igho; Roberts, Nia; Miller, Franklin G.; Howick, Jeremy
• Is Part Of: Journal of evidence-based medicine. Volume 10:Issue 2(2017:May)
• Page Start: 97
• Page End: 107
• Publication Date: 2017-05-30
• Subjects: ethics -- expectation -- nondeceptive -- placebo -- suggestion; Evidence-based medicine -- Periodicals; Systematic reviews (Medical research) -- Periodicals; 616.005
• DOI: 10.1111/jebm.12251
• Languages: English
• ISSNs: 1756-5383

Abstract

Abstract: Objective: To investigate the clinical efficacy of open‐label placebos compared with no treatment in a systematic review and meta‐analysis. Methods: We searched the Cochrane Injuries Group's Specialised Register, The Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE(R) In‐Process & Other Non‐Indexed Citations (OvidSP), EMBASE (OvidSP), and clinical trials registers and screened reference lists. The search was run on 27 th April 2015. We included all randomized controlled trials of any medical condition with open‐label placebo and no‐treatment groups. Authors independently assessed records and extracted data. We excluded nonrandomized trials and nonclinical studies. Risk of bias was assessed using Cochrane criteria. We used random‐effects model for meta‐analysis. Results: We screened 348 publications, assessed 24 articles for eligibility and identified five trials (260 participants) that met inclusion criteria. The clinical conditions were: irritable bowel syndrome, depression, allergic rhinitis, back pain, and attention deficit hyperactivity disorder. The risk of bias was moderate. We found a positive effect for nondeceptive placebos (standardized mean difference 0.88, 95% CI 0.62 to 1.14, P < 0.00001, I 2 = 1%). Conclusions: Open‐label placebos appear to have positive clinical effects compared to no treatment. Caution is warranted when interpreting these results due to the limited number of trials identified, lack of blinding, and the fact that positive messages were included alongside open‐label placebos. Larger definitive trials are now warranted to explore the potential patient benefit of open‐label placebos, to investigate the relative contributions of positive suggestions, and ethical implications.